Welcome to the e-CCO Library Archive!

Filter:
P547

Phlegmonous Crohn's disease: A review of outcomes at a tertiary centre

Authors:

K.V. Patel*1, C.I. Amadi1, S. Fong1, I. Nasr1, N. Griffin2, E. Westcott3, A.B. Williams3, A.A. Darakhshan3, S.H. Anderson1, P.M. Irving1, J.D. Sanderson1

1Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom, 2Guy's and St Thomas' NHS Foundation Trust, Radiology, London, United Kingdom, 3Guy's and St Thomas' NHS Foundation Trust, Colorectal Surgery, London, United Kingdom

P548.

Biological agents in Crohn's disease: When?

Authors:

E. Saritas Yuksel1, C. Cekic1, F. Topal1, Z.Z. Gumus1, B. Unsal1, Z. Akpinar1, 1IKÇU Ataturk Research and Teaching Hospital, Gastroenterology, Izmir, Turkey

P548. Deep remission: a recurrent feature in patients with Crohn's disease and long term biologic therapy
Authors:

R. Vadan1, L. Gheorghe1, R. Cerban1, B. Cotruta1, L. Tugui1, I. Stanel1, C. Angelescu1, I. Bancila1, M. Diculescu1, C. Gheorghe1, 1Fundeni Clinical Institute, Gastroenterology and Hepatology Center, Bucharest, Romania

P548

Early intervention of infliximab prevent reoperation for the recurrence of Crohn's disease

Authors:

M. Ishii*1, K.-i. Tarumi1, T. Kamada1, M. Fujita1, H. Matsumoto1, T. Murao1, R. Nakato1, M. Osawa1, S. Hirai1, S. Fukushima1, N. Manabe2, H. Kusunoki3, A. Shiotani1, J. Hata2, K. Haruma1

1Kawasaki Medical School, Division of Gastroenterology Department of Internal Medicine, Kurashiki, Japan, 2Kawasaki Medical School, Clinical Pathology and Laboratory Medicine, Kurashiki, Japan, 3Kawasaki Medical School, Genaral Medicine, Kurashiki, Japan

P549.

Azathioprine in the elderly – Is it tolerated and is it safe?

Authors:

S. Dharmasiri, H. Johnson, S. McLaughlin, S. Weaver, Royal Bournemouth Hospital, Depatment of Gastroenterology, Bournemouth, United Kingdom

P549. Dose optimization is effective in patients with ulcerative colitis losing response to infliximab: a collaborative multicentre retrospective study
Authors:

M. Cesarini1, K. Katsanos2, P. Ellul3, P. Lakatos4, K. Papamichael5, F. Caprioli6, E. Tsianos2, G. Mantzaris5, S. Danese7, G. Fiorino7, 1Sapienza University of Rome, Medicina Interna e Specialità Mediche, Rome, Italy, 2University of Ioannina, Greece, 3Mater Dei Hospital, Malta, 4Semmelweis University, Budapest, Hungary, 5Evangelismos Hospital, Athens, Greece, 6University of Milan, Italy, 7IRCCS Humanitas, IBD Center, Rozzano, Italy

P549

Short and long term therapeutic Efficacy of Oral Nutritional Therapy in pediatric Crohn's Disease ; A Single Center Experience

Authors:

H.J. Kim*, J.M. Cho, K.M. Kim, S.H. Oh

Seoul Asan Medical Center , Pediatrics , Seoul , South Korea

P550.

Azathioprine and lymphocyte count in paediatric inflammatory bowel disease

Authors:

E. Volonaki, V. La Vela, R. Dziubac, F. Kiparissi, N. Shah, K.J. Lindley, M. Elawad, Great Ormond Street Hospital, Paediatric Gastroenterology, London, United Kingdom

P550. Diagnosing and treating pediatric Crohn's disease patients: is there a difference between adult and pediatric gastroenterologists' practices? Results of the BELCRO cohort
Authors:

E. De Greef1, B. Maus2, I. Hoffman3, F. Smets4, S. Van Biervliet5, M. Scaillon6, B. Hauser7, I. Paquot8, P. Alliet9, W. Arts10, O. Dewit11, H. Peeters12, F. Baert13, G. D'Haens14, J.-F. Rahier15, I. Etienne16, O. Bauraind8, A. Van Gossum17, S. Vermeire18, F. Fontaine19, V. Muls20, E. Louis21, F. Van De Mierop22, J. Coche23, J.J. Mahachie2, K. Van Steen2, G. Veereman24, 1UZ Brussels, Pediatric Gastroenterology, Jette, Belgium, 2ULG, Montefiore Institute, Liege, Belgium, 3Uz Gasthuisberg, Pediatric Gastroenterology, Leuven, Belgium, 4UCL St Luc, Pediatric Gastroenterology, Brussel, Belgium, 5UZ Gent, Pediatric Gastroenterology, Gent, Belgium, 6Hôpital des enfants Reine Paola, Pediatric Gastroenterology, Brussel, Belgium, 7UZ Brussels, Pediatric Gastroenterology, Brussel, Belgium, 8CHC Clinique de l'Esperance, Pediatric Gastroenterology, Liege, Belgium, 9Jessa Hospital, Pediatric Gastroenterology, Hasselt, Belgium, 10ZOL, Pediatric Gastroenterology, Genk, Belgium, 11UCL St Luc, Gastroenterology, Brussel, Belgium, 12UZ Gent, Gastroenterology, Gent, Belgium, 13Heilig Hart Hospital, Gastroenterology, Roesselare, Belgium, 14AMC, Gastroenterology, Amsterdam, Netherlands, 15UCL Montgodinne, Gastroenterology, Mont Godinne, Belgium, 16CHR Citadelle, Pediatric Gastroenterology, Liege, Belgium, 17ULB Erasme, Gastroenterology, Brussel, Belgium, 18Uz Gasthuisberg, Gastroenterology, Leuven, Belgium, 19CHU St Joseph, Gastroenterology, Liege, Belgium, 20ULB St Pierre, Gastroenterology, Brussel, Belgium, 21ULG, Gastroenterology, Liege, Belgium, 22AZ St Augustinus, Gastroenterology, Wilrijk, Belgium, 23Clinique Saint Pierre, Gastroenterology, Ottignies, Belgium, 24UZ Brussels, Pediatric Gastroenterology, Brussels, Belgium

P550

Long - term efficacy of Tacrolimus in Inflammatory Bowel Disease: a retrospective pilot study

Authors:

I. Rodríguez - Lago*1, O. Merino2, Ó. Nantes3, I. Moraleja1, J.L. Cabriada1

1Hospital Galdakao - Usansolo, Gastroenterology Department, Usansolo, Spain, 2Hospital Universitario de Cruces, Gastroenterology Department, Bilbao, Spain, 3Complejo Hospitalario de Navarra, Gastroenterology Department, Pamplona, Spain

P551.

Association between haemoglobin levels, serum ferritin and faecal and serum markers of inflammation in patients with IBD

Authors:

N.S. Taylor, S. Cotton, L.-A. McCabe, D.A. Lloyd, J.N. Gordon, Royal Hampshire County Hospital, Hampshire Hospitals NHS Foundation Trust, Department of Gastroenterology, Winchester, United Kingdom

P551. Detection of anti infliximab antibodies in patients with inflammatory bowel disease (IBD) in the presence of infliximab by homogeneous liquid phase anti infliximab mobility shift assay
Authors:

A. Eser1, C. Primas1, S. Haunstein2, S. Lockton2, S. Wang2, S. Singh2, W. Reinisch1, 1Medical University of Vienna, Vienna, Austria, 2Prometheus Labs Inc, San Diego, United States

P551

Hospital readmissions in patients with inflammatory bowel disease: A UK single centre experience

Authors:

L. Chan*, E. Wood, L. Fang, J. Limdi

Pennine Acute Hospitals NHS Trust, Gastroenterology, Greater Manchester, United Kingdom

P552.

Association between Week 8 Mayo subscores and hospitalisation rates in adalimumab-treated patients with ulcerative colitis from ULTRA 1 and ULTRA 2

Authors:

W. Reinisch1, W.J. Sandborn2, B. Feagan3, S. Ghosh4, A. Robinson5, M. Skup5, J. Petersson5, B. Huang5, A. Lazar6, R. Thakkar5, 1McMaster University, Department of Medicine, Hamilton, Canada, 2University of California San Diego, Division of Gastroenterology, La Jolla, United States, 3Robarts Clinical Trials Inc., Robarts Research Institute, Western University, London, Ontario, Canada, 4University of Calgary, Department of Medicine, Calgary, Canada, 5AbbVie Inc, GPRD, North Chicago, United States, 6AbbVie Deutschland GmbH & Co, KG, GPRD, Ludwigshafen, Germany

P552. Current practice in the diagnosis and management of IBD-associated anemia and iron deficiency in Germany: The German AnemIBD study
Authors:

I. Blumenstein1, S. Vollmer2, W. Klemm3, G. Virgin4, S. Weber-Mangal4, J. Stein5, 1Frankfurt University Hospital, Medical Dpt. 1, Frankfurt, Germany, 2Gastroenterological Practice, Göppingen, Germany, 3Gastroenterological Practice, Cottbus, Germany, 4Vifor Pharma Germany, Munich, Germany, 5Crohn Colitis Zentrum Rhein-Main, Frankfurt, Germany

P552

Prognosis of patients with Ulcerative Colitis in remission after thiopurines withdrawal

Authors:

E. Moreno Rincón*1, F.J. Serrano Ruiz1, J.M. Benítez Cantero1, J.M. Vázquez Morón2, H. Pallarés Manrique2, J.M. Herrera Justiniano3, E. Leo Carnerero3, M.D.R. Gómez García4, M.J. Cabello Tapia4, M. Castro Fernández5, M. Rojas Feria5, L. Castro Laria6, F. Argüelles Arias6, R. Camargo Camero7, G. Alcaín Martínez7, E. Iglesias Flores1, V. García Sánchez1

1Hospital Universitario Reina Sofía, Gastroenterology Unit, Córdoba, Spain, 2Hospital Juan Ramón Jiménez, Gastroenterology, Huelva, Spain, 3Hospital Universitario Virgen del Rocío, Gastroenterology, Sevilla, Spain, 4Hospital Universitario Virgen de las Nieves, Digestive Department, Granada, Spain, 5Hospital de Valme, Gastroenterology, Sevilla, Spain, 6Hospital Universitario Virgen Macarena, Gastroenterology, Sevilla, Spain, 7Hospital Universitario Virgen de la Victoria, Gastroenterology, Malaga, Spain

P553.

A single-centre pilot study examining internet use for health related information among patients with inflammatory bowel disease

Authors:

K. Greveson1, T. Shepherd2, M. Hamilton1, C. Murray1, 1Royal Free Hospital, Gastroenterology, London, United Kingdom, 2Royal Free Hospital, Gastroenterology, London, United Kingdom

P553. Coping strategies for worsening conditions and their perceived effectiveness in patients with inflammatory bowel disease
Authors:

M. Tanaka1, A. Kawakami1, Y. Iwao2, T. Fukushima3, M. Nishigaki1, M. Suzuki1, H. Sanada1, N. Yamamoto-Mitani1, 1The University of Tokyo, School of Health Sciences and Nursing, Tokyo, Japan, 2Keio University School of Medicine, Center for Preventive Medicine, Tokyo, Japan, 3Matsushima Clinic, Yokohama, Japan

P553

An Evaluation Study of Lactobacillus Brevis CD2 in Orofacial Granuolomatosis

Authors:

R. Goel*1, 2, M. Ormond1, E. Hullah1, S. Nayee1, M. Escudier1, J. Sanderson3

1Guy's & St Thomas' Hospitals, Oral Medicine, London, United Kingdom, 2Guy's & St Thomas' Hospitals, Gastroenterology, London, United Kingdom, 3Guy's & St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom

P554.

A prospective assessment of antidrug antibody response over time by a new ELISA in patients with IBD treated with infliximab

Authors:

V. Ussia, L. Ceccarelli, S. Maltinti, G. Di Fluri, M.G. Mumolo, V. Bolognesi, A. Ricchiuti, M. Bellini, S. Marchi, F. Costa, Pisa University, Gastroenterology, Pisa, Italy